Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka Dawn [1 ]
Joyner, Kayla Rena [2 ,3 ]
机构：
[1] Winchester Med Ctr, Pharm Dept, Winchester, VA 22601 USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharm Practice, Winchester, VA USA
[3] Winchester Med Ctr, Trauma & Acute Care Surg, Winchester, VA USA
来源：
ANNALS OF PHARMACOTHERAPY | 2023年 / 57卷 / 09期
关键词：
D O I：
10.1177/10600280221144936
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1118 / 1119
页数：2
相关论文
共 50 条
  • [31] Tocilizumab for severe COVID-19 pneumonia
    Mourad, Jean-Jacques
    Azria, Philippe
    LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E659
  • [32] Commenting on baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study
    Wei, James Cheng Chung
    Kuo, Poi
    Shih, Po-Cheng
    CRITICAL CARE, 2024, 28 (01)
  • [33] Comments on "Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study"
    Li, Rong
    Wang, Juanjuan
    Li, Qian
    Guo, Qianyue
    Zhao, Jun Kang
    Wei, James Cheng-Chung
    Zhang, Li-Yun
    CRITICAL CARE, 2024, 28 (01)
  • [34] Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study
    Chilimuri, Sridhar
    Sun, Haozhe
    Alemam, Ahmed
    Kang, Kyoung-Sil
    Lao, Peter
    Mantri, Nikhitha
    Schiller, Lawrence
    Sharabun, Myroslava
    Shehi, Elona
    Tejada, Jairo
    Yugay, Alla
    Nayudu, Suresh Kumar
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (02) : 440 - 446
  • [35] Why tocilizumab could be an effective treatment for severe COVID-19?
    Binqing Fu
    Xiaoling Xu
    Haiming Wei
    Journal of Translational Medicine, 18
  • [36] Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19
    Singla, Karan
    Puri, Goverdhan D.
    Niyogi, Subhrashis Guha
    Mahajan, Varun
    Kajal, Kamal
    Bhalla, Ashish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [37] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [38] Tocilizumab for the treatment of COVID-19
    Fernandez-Ruiz, Mario
    Lopez-Medrano, Francisco
    Aguado, Jose Maria
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 431 - 434
  • [39] Tocilizumab for the treatment of COVID-19
    Flisiak, Robert
    Flisiak-Jackiewicz, Marta
    Rzymski, Piotr
    Zarebska-Michaluk, Dorota
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (08) : 791 - 797
  • [40] High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial
    Naik, Naveen B.
    Puri, Goverdhan D.
    Kajal, Kamal
    Mahajan, Varun
    Bhalla, Ashish
    Kataria, Sandeep
    Singla, Karan
    Panigrahi, Pritam
    Singh, Ajay
    Lazar, Michelle
    Chander, Anjuman
    Ganesh, Venkata
    Hazarika, Amarjyoti
    Suri, Vikas
    Goyal, Manoj K.
    Pandey, Vijayant Kumar
    Kaloria, Narender
    Samra, Tanvir
    Saini, Kulbhushan
    Soni, Shiv L.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
12345